▴ Talipexole is a dopamine D2receptor agonist, with activity at both pre- and postsynaptic D2receptors. The drug also has &agr;2-adrenoceptor agonist activity.▴ In a primate model of Parkinson's disease, talipexole dose-dependently improved motor activity and parkinsonian symptoms, and beneficial effects were additive when combined with levodopa.▴ Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.▴ In a large comparative trial in patients with Parkinson's disease, talipexole was associated with a higher response rate and a lower incidence of gastrointestinal adverse events than bromocriptine, although drowsiness was more common among talipexole recipients.▴ The most frequently reported adverse events associated with talipexole are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints such as nausea, gastrointestinal discomfort and loss of appetite.